Sealantis, an Israel-based developer of protein-free alga-mimetic tissue adhesives, has obtained the Conformité Européenne (CE) mark for its protein-free bioresorbable sealant Seal-V.
The CE mark will allow the company to sell its product on the European market.
The Seal-V sealant is used to achieve haemostasis, a surgical procedure to stop the flow of blood from damaged blood vessels.
However, unlike haemostasis, it does not depend on the presence of blood to seal the leak areas, and can be used as a prophylactic sealant.
Additionally, it is developed based on an alga-mimetic formulation, which allows it to bind strongly to both blood vessels and synthetic grafts in wet and moist conditions.
The protein-free composition also makes the sealant free of the risks associated with the use of protein-based products.
Sealantis CEO Tomer Fuchs said they are pleased to be able to introduce Seal-V to the European market and to provide surgeons with a new and better option for controlling bleeding from suture-lines.
Sealantis chairman Dr Zeev Gilkis said, "Sealantis has been working closely with surgeons to leverage the extraordinary capabilities of its alga-mimetic technology and design products that will be strongly positioned in the multibillion dollar market of wound closure."
The company is currently looking for partners to launch the Seal-V.
In addition to Seal-V, Sealantis also has other products in the pipeline including gastro-intestinal sealant for preventing the leakage of intestinal content from anastomose, an adhesive for space obliteration in esthetic surgeries and devices for site-specific drug delivery.